Stock ROSGQ ROSETTA GENOMICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Rosetta Genomics Ltd.

Equities

ROSGQ

IL0011026494

Market Closed - OTC Markets
Other stock markets
 09:34:46 2024-02-12 am EST 		5-day change 1st Jan Change
0.0001 USD +9,900.00% Intraday chart for Rosetta Genomics Ltd. -.--% -.--%
2018 Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd.. CI
2018 Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd..
CI
Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index
CI
Rosetta Genomics Ltd. Announces Resignation of Ken Berlin as President and CEO, Effective April 18, 2018
CI
Genoptix, Inc. and Rosetta Genomics Ltd. Enter into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide
CI
Genoptix, Inc. completed the acquisition of PDx Business of Rosetta Genomics Ltd..
CI
Genoptix, Inc. entered into a definitive agreement to acquire PDx Business of Rosetta Genomics Ltd. for $1 million.
CI
Genoptix, Inc. entered into a merger agreement to acquire Rosetta Genomics Ltd. for $8 million.
CI
Genoptix, Inc. cancelled the proposed acquisition of Rosetta Genomics Ltd..
CI
Genoptix, Inc. entered into a term sheet agreement to acquire Rosetta Genomics Ltd..
CI
Rosetta Genomics Ltd. Announces Resignation of David Sidransky as Director
CI
Certain Ordinary Shares of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.
CI
Certain Stock Options of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.
CI
Certain Warrants of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.
CI
Certain Restricted Stock Units of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.
CI
Pragmin Prognosis cancelled the acquisition of CYNOGEN Inc. from Rosetta Genomics Ltd..
CI
Rosetta Genomics Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017
CI
Rosetta Genomics Is Considering Options To Sell Pragmin
CI
Rosetta Genomics Ltd. announced that it has received $2 million in funding
CI
Rosetta Genomics Ltd. announced that it expects to receive $2 million in funding
CI
Pragmin Prognosis entered into a definitive agreement to acquire CYNOGEN Inc. from Rosetta Genomics Ltd. for $2.9 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROSGQ Stock
  4. News Rosetta Genomics Ltd.